6-(4,4,5,5-四甲基-1,3,2-二氧杂硼硼烷-2-基)-1H-吡咯[3,2-b]吡啶 | 1045855-91-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯并吡啶类
• 中文名称: 6-(4,4,5,5-四甲基-1,3,2-二氧杂硼硼烷-2-基)-1H-吡咯[3,2-b]吡啶
• 中文别名: 6-(4,4,5,5-四甲基-1,3,2-二氧硼烷-2-基)-1H-吡咯并[3,2-b]吡啶
• 英文名称: 6-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrrolo[3,2-b]pyridine
• CAS: 1045855-91-1
• 化学式: C₁₃H₁₇BN₂O₂
• 分子量: 244.1
• InChiKey: LVVACKKTPDWXJM-UHFFFAOYSA-N

物化性质

• 沸点：
  405.7±25.0 °C(Predicted)
• 密度：
  1.15±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.86
• 重原子数：
  18
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  47.1
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• WGK Germany：
  3
• 海关编码：
  2934999090

反应信息

• 作为反应物：
  描述：

  2-chloro-5-(4-(methylsulfonyl)benzyl)-5,6,6a,7,9,10-hexahydro-[1,4]oxazino[3,4-h]pteridine 、 6-(4,4,5,5-四甲基-1,3,2-二氧杂硼硼烷-2-基)-1H-吡咯[3,2-b]吡啶 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 作用下， 以 1,4-二氧六环 、 碳酸氢钠 为溶剂， 生成 5-(4-(methylsulfonyl)benzyl)-2-(1H-pyrrolo[3,2-b]pyridin-6-yl)-5,6,6a,7,9,10-hexahydro-[1,4]oxazino[3,4-h]pteridine
  参考文献：
  名称：

  N-substituted oxazinopteridines and oxazinopteridinones

  摘要：

  本发明涉及公式1的化合物及其药学上可接受的盐，其中Ar、R1、R2、R3、G1、G2和m在说明书中有定义。本公开还涉及制备公式1化合物的材料和方法，以及包含它们的制药组合物，并用于治疗炎症性疾病、心血管疾病、癌症和其他与PI3Kδ相关的疾病的用途。

  公开号：

  US08791107B2

文献信息

• Substituted Benzo-Imidazo-Pyrido-Diazepine Compounds
  申请人：Ashwell Mark A.

  公开号：US20120108574A1

  公开（公告）日：2012-05-03

  The present invention relates to substituted benzo-imidazo-pyrido-diazepine compounds and methods of synthesizing these compounds. The present invention also relates to pharmaceutical compositions containing substituted benzo-imidazo-pyrido-diazepine compounds and methods of treating cell proliferative disorders, such as cancer, by administering these compounds and pharmaceutical compositions to subjects in need thereof.

  本发明涉及取代苯并咪唑吡啶-二氮杂环化合物及其合成方法。本发明还涉及含有取代苯并咪唑吡啶-二氮杂环化合物的制药组合物以及通过向需要此类化合物和制药组合物的受试者施用这些化合物和制药组合物来治疗细胞增殖性疾病，如癌症的方法。
• N-SUBSTITUTED OXAZINOPTERIDINES AND OXAZINOPTERIDINONES
  申请人：Chang Edcon

  公开号：US20120220575A1

  公开（公告）日：2012-08-30

  Disclosed are compounds of Formula 1, and pharmaceutically acceptable salts thereof, wherein Ar, R 1 , R 2 , R 3 , G 1 , G 2 , and m are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, to pharmaceutical compositions which contain them, and to their use for treating inflammatory disorders, cardiovascular disease, cancer, and other conditions associated with PI3Kδ.

  本发明涉及公式1的化合物及其药学上可接受的盐，其中Ar、R1、R2、R3、G1、G2和m在说明书中有定义。本公开还涉及制备公式1化合物的材料和方法，包括含有它们的制药组合物，以及它们用于治疗炎症性疾病、心血管疾病、癌症和与PI3Kδ相关的其他疾病的用途。
• Apoptosis signal-regulating kinase inhibitors
  申请人：Corkey Britton

  公开号：US08552196B2

  公开（公告）日：2013-10-08

  The present invention relates to compounds of Formula (I): wherein X1, X2, X3, X4, X5, X6, X7, X8, R1, R2, R3 are defined above. The compounds have apoptosis signal-regulating kinase (“ASK1”) inhibitory activity, and are thus useful in the treatment of ASK1-mediated conditions, including autoimmune disorders, inflammatory diseases, cardiovascular diseases and neurodegenerative diseases. The invention also relates to pharmaceutical compositions comprising one or more of the compounds of Formula (I), and to methods of preparing the compounds of Formula (I).

  本发明涉及式（I）的化合物：其中X1、X2、X3、X4、X5、X6、X7、X8、R1、R2、R3如上所定义。这些化合物具有凋亡信号调节激酶（"ASK1"）抑制活性，因此可用于治疗ASK1介导的疾病，包括自身免疫性疾病、炎症性疾病、心血管疾病和神经退行性疾病。本发明还涉及包含一个或多个式（I）化合物的制药组合物，以及制备式（I）化合物的方法。
• APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS
  申请人：Corkey Britton

  公开号：US20130035339A1

  公开（公告）日：2013-02-07

  The present invention relates to compounds of Formula (I): wherein X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , X 7 , X 8 , R 1 , R 2 , R 3 are defined above. The compounds have apoptosis signal-regulating kinase (“ASK1”) inhibitory activity, and are thus useful in the treatment of ASK1-mediated conditions, including autoimmune disorders, inflammatory diseases, cardiovascular diseases and neurodegenerative diseases. The invention also relates to pharmaceutical compositions comprising one or more of the compounds of Formula (I), and to methods of preparing the compounds of Formula (I).

  本发明涉及式(I)的化合物：其中X1，X2，X3，X4，X5，X6，X7，X8，R1，R2，R3如上所定义。该化合物具有凋亡信号调节激酶（“ASK1”）抑制活性，因此在治疗ASK1介导的疾病中有用，包括自身免疫性疾病，炎症性疾病，心血管疾病和神经退行性疾病。本发明还涉及包含一种或多种式(I)化合物的制药组合物，以及制备式(I)化合物的方法。
• Substituted benzo[f]lmidazo[1,2-d]pyrido[2,3-b][1,4]diazepine compounds
  申请人：Ashwell Mark A.

  公开号：US08569331B2

  公开（公告）日：2013-10-29

  The present invention relates to substituted benzo[f]imidazo[1,2-d]pyrido[2,3-b][1,4]diazepine compounds and methods of synthesizing these compounds. The present invention also relates to pharmaceutical compositions containing substituted benzo[f]imidazo[1,2-d]pyrido[2,3-b][1,4]diazepine compounds and methods of treating cell proliferative disorders, such as cancer, by administering these compounds and pharmaceutical compositions to subjects in need thereof.

  本发明涉及取代的苯并[f]咪唑并[1,2-d]吡啶[2,3-b][1,4]二氮杂环化合物及其合成方法。本发明还涉及含有取代的苯并[f]咪唑并[1,2-d]吡啶[2,3-b][1,4]二氮杂环化合物的制药组合物，以及通过将这些化合物和制药组合物用于需要的受体中来治疗细胞增殖性疾病，如癌症的方法。